Repurpose Open Data to Discover Therapeutics for COVID-19 Using Deep Learning
Xiangxiang Zeng,Xiang Song,Tengfei Ma,Xiaoqin Pan,Yadi Zhou,Yuan Hou,Zheng Zhang,Kenli Li,George Karypis,Feixiong Cheng
DOI: https://doi.org/10.1021/acs.jproteome.0c00316
2020-07-12
Journal of Proteome Research
Abstract:There have been more than 2.2 million confirmed cases and over 120 000 deaths from the human coronavirus disease 2019 (COVID-19) pandemic, caused by the novel severe acute respiratory syndrome coronavirus (SARS-CoV-2), in the United States alone. However, there is currently a lack of proven effective medications against COVID-19. Drug repurposing offers a promising route for the development of prevention and treatment strategies for COVID-19. This study reports an integrative, network-based deep-learning methodology to identify repurposable drugs for COVID-19 (termed CoV-KGE). Specifically, we built a comprehensive knowledge graph that includes 15 million edges across 39 types of relationships connecting drugs, diseases, proteins/genes, pathways, and expression from a large scientific corpus of 24 million PubMed publications. Using Amazon's AWS computing resources and a network-based, deep-learning framework, we identified 41 repurposable drugs (including dexamethasone, indomethacin, niclosamide, and toremifene) whose therapeutic associations with COVID-19 were validated by transcriptomic and proteomics data in SARS-CoV-2-infected human cells and data from ongoing clinical trials. Whereas this study by no means recommends specific drugs, it demonstrates a powerful deep-learning methodology to prioritize existing drugs for further investigation, which holds the potential to accelerate therapeutic development for COVID-19.The Supporting Information is available free of charge at <a class="ext-link" href="/doi/10.1021/acs.jproteome.0c00316?goto=supporting-info">https://pubs.acs.org/doi/10.1021/acs.jproteome.0c00316</a>.Supplementary Figure 1. Diagram illustrating the prioritization of drugs based on their distance to COVID-19 in the treatment relation space. Supplementary Table 1. Details of the five categories of relationships in our KG. Supplementary Table 2. Statistics of nodes (entity) and edges (relation) in our KG (<a class="ext-link" href="/doi/suppl/10.1021/acs.jproteome.0c00316/suppl_file/pr0c00316_si_001.pdf">PDF</a>)This article has not yet been cited by other publications.
biochemical research methods